Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study
Almanza-Aguilera E, Martínez-Huélamo M, López-Hernández Y, Guiñón-Fort D, Guadall A, Cruz M, Perez-Cornago A, Rostgaard-Hansen A, Tjønneland A, Dahm C, Katzke V, Schulze M, Masala G, Agnoli C, Tumino R, Ricceri F, Lasheras C, Crous-Bou M, Sánchez M, Aizpurua-Atxega A, Guevara M, Tsilidis K, Chatziioannou A, Weiderpass E, Travis R, Wishart D, Andrés-Lacueva C, Zamora-Ros R. Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study. Cancers 2024, 16: 4116. PMID: 39682302, PMCID: PMC11639937, DOI: 10.3390/cancers16234116.Peer-Reviewed Original ResearchProstate cancer riskProstate cancerPCa riskBiomarkers of food intakeMultivariate conditional logistic regression analysisNested case-control analysisAdvanced PCa riskFatal prostate cancerCancer and NutritionConditional logistic regression analysisOverall PCa riskEuropean Prospective InvestigationMetabolite concentrationsCase-control analysisCase-control pairsLogistic regression analysisClinically relevant tumor subtypesMetabolomics approachTumor subtypesProspective InvestigationClinical subtypesCancer riskFood intakeMetabolic alterationsEPIC study